THE WOODLANDS, Texas--(BUSINESS WIRE)--Dec. 1, 2005--PharmaFrontiers Corp (OTC:PFTR), a company involved in the development of novel cell therapies, including one for multiple sclerosis, which is about to enter Phase IIb clinical trials, has appointed Mathilda Mandel, M.D. to its clinical advisory board. Dr. Mandel is the director of the Blood Bank and Transfusion Center at Sheba Medical Center in Tel-Hshomer, Israel, a position she has held since 1994.
